TW200621231A - Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator - Google Patents

Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator

Info

Publication number
TW200621231A
TW200621231A TW094129674A TW94129674A TW200621231A TW 200621231 A TW200621231 A TW 200621231A TW 094129674 A TW094129674 A TW 094129674A TW 94129674 A TW94129674 A TW 94129674A TW 200621231 A TW200621231 A TW 200621231A
Authority
TW
Taiwan
Prior art keywords
receptor modulator
selective
phenyl
treat
androgen receptor
Prior art date
Application number
TW094129674A
Other languages
Chinese (zh)
Inventor
Hua-Zhu Ke
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200621231A publication Critical patent/TW200621231A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to a pharmaceutical combination of a selective estrogen receptor modulator (SERM) and a selective androgen receptor modulator (SARM). Particularly, this invention relates to a pharmaceutical composition comprising cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8- tetrahydronapthalene-2-ol, or a pharmaceutically acceptable salt thereof; and a selective androgen receptor modulator. This invention also relates to methods of treatment using the pharmaceutical composition comprising cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronapthalene- 2-ol, or a pharmaceutically acceptable salt thereof: and a selective androgen receptor modulator. Particularly, this invention is directed to methods to prevent and/or restore age-related decline in muscle mass and strength, treat a wasting disease, treat a condition that prevents with low bone mass, increase muscle mass, increase lean body mass, decrease fat body mass, treat bone fracture and muscle damage and treat female sexual dysfunction in mammals, including humans.
TW094129674A 2004-08-31 2005-08-30 Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator TW200621231A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60592504P 2004-08-31 2004-08-31

Publications (1)

Publication Number Publication Date
TW200621231A true TW200621231A (en) 2006-07-01

Family

ID=35735140

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094129674A TW200621231A (en) 2004-08-31 2005-08-30 Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator

Country Status (2)

Country Link
TW (1) TW200621231A (en)
WO (1) WO2006024931A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2447061C1 (en) * 2010-10-22 2012-04-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Ярославский государственный технический университет"(ЯГТУ) Novel 4-(azacycloalkyl)phthalonitriles and synthesis method thereof
US20150071857A1 (en) * 2012-03-07 2015-03-12 Ligand Pharmaceuticals, Inc. Steroid hormone and cholesterol pathways as one unified homeostatic system
EP3094323A4 (en) * 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
US20230012570A1 (en) * 2019-11-20 2023-01-19 Medshine Discovery Inc. Bicyclic compound used as selective androgen receptor modulator

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA993975B (en) * 1998-06-16 2000-12-15 Pfizer Prod Inc Combination therapy for musculoskeletal frailty.
EP1501512A4 (en) * 2002-04-30 2009-11-18 Merck & Co Inc 4-azasteroid derivatives as androgen receptor modulators

Also Published As

Publication number Publication date
WO2006024931A2 (en) 2006-03-09
WO2006024931A3 (en) 2006-05-26

Similar Documents

Publication Publication Date Title
TW200501983A (en) Uses of anti-insulin-like growth factor I receptor antibodies
WO2012005500A3 (en) Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration
EA200600820A1 (en) METHODS OF TREATMENT, MODIFICATION AND ELIMINATION OF PATIENTS USING 1-OXO-2- (2,6-DIOXOPYPERIDIN-3-IL) -4-METHYLISYNDOLINE
WO2005107726A3 (en) Method for the treatment of back pain
YU30004A (en) Use of flibanserin in the treatment of sexual disorders
MXPA06013133A (en) Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction.
MY136841A (en) Carbamate-substituted pyrazolopyridines
WO2004019884A3 (en) Agents and methods for enhancing bone formation
JP2008534503A5 (en)
NO20055531L (en) Preparation for improved cognition and memory
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
HK1105201A1 (en) Muscle relaxation accelerator and therapeutic agent for muscular tissue diseases such as muscle relaxation failure
WO2020092618A9 (en) Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
EP1348466A3 (en) Method for treating pain with adenosine-tetraphosphates
EA200801310A1 (en) PHARMACEUTICAL PREPARATIONS AND THEIR APPLICATION IN THE TREATMENT OF SEXUAL DYSFUNCTION IN WOMEN
WO2007042040A3 (en) TREATMENT OF RETINOPATHIES USING GFRα3 AGONISTS
TW200621231A (en) Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
EP1677806A4 (en) Methods for treating acute and overuse sprain and strain using hyaluronic acid
EP1542664A4 (en) Methods and compositions for treatment of macular and retinal disease
RU2020120156A (en) TREATMENT AND LOSS OF BONE TISSUE CAUSED BY ANDROGENIC DEPRIVATION THERAPY USING CIS-CLOMIFEN
TW200501934A (en) Therapeutic causing contraction of mucosal tissue, method of treating diseases relating to mucosal tissues, injector and therapeutic set
PL1732551T3 (en) Perhexilin for treating chronic heart failure
WO2000076500A3 (en) Compound for use as a medicament for treatment of disorders involving bronchocontraction
WO2004029025A3 (en) Methods and compositions for the treatment of autoimmune disorders using clofarabine